Vanguard Group Inc. Has $132.46 Million Position in Certara, Inc. (NASDAQ:CERT)

Vanguard Group Inc. increased its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 0.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,437,089 shares of the company's stock after acquiring an additional 38,068 shares during the quarter. Vanguard Group Inc. owned about 7.73% of Certara worth $132,455,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of CERT. LPL Financial LLC grew its position in Certara by 17.3% during the fourth quarter. LPL Financial LLC now owns 112,624 shares of the company's stock worth $1,288,000 after buying an additional 16,586 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Certara in the 4th quarter worth approximately $276,000. Sei Investments Co. grew its holdings in shares of Certara by 2.6% during the 4th quarter. Sei Investments Co. now owns 1,137,612 shares of the company's stock worth $12,116,000 after purchasing an additional 28,809 shares in the last quarter. Teacher Retirement System of Texas increased its position in shares of Certara by 13.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company's stock valued at $48,542,000 after purchasing an additional 557,348 shares during the period. Finally, Thrivent Financial for Lutherans raised its stake in shares of Certara by 128.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 196,391 shares of the company's stock valued at $2,091,000 after purchasing an additional 110,481 shares in the last quarter. Institutional investors own 73.96% of the company's stock.

Certara Price Performance

CERT stock traded up $2.40 during trading on Friday, hitting $12.91. 9,669,818 shares of the stock traded hands, compared to its average volume of 1,136,032. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -64.55, a P/E/G ratio of 9.29 and a beta of 1.64. Certara, Inc. has a one year low of $8.64 and a one year high of $18.38. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a 50 day simple moving average of $11.61 and a 200 day simple moving average of $11.37.

Analyst Ratings Changes

CERT has been the topic of a number of recent research reports. Robert W. Baird lifted their price target on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday. TD Cowen started coverage on shares of Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price on the stock. William Blair reissued a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Stephens restated an "overweight" rating and set a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. Finally, Barclays lowered their price objective on Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a research note on Thursday. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Certara presently has a consensus rating of "Moderate Buy" and an average target price of $15.50.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.